The ability to reprogram somatic cells to induced pluripotent stem cells (iPSCs) has revolutionized the way of modeling human disease. Especially for the modeling of rare human monogenetic diseases with limited numbers of patients available worldwide and limited access to the mostly affected tissues, iPSCs have become an invaluable tool. To study rare diseases affecting neurotransmitter biosynthesis and neurotransmission, stem cell models carrying patient-specific mutations have become highly important as most of the cell types present in the human brain and the central nervous system (CNS), including motoneurons, neurons, oligodendrocytes, astrocytes, and microglia, can be differentiated from iPSCs following distinct developmental programs. Differentiation can be performed using classical 2D differentiation protocols, thereby generating specific subtypes of neurons or glial cells in a dish. On the other side, 3D differentiation into Borganoids^opened new ways to study misregulated developmental processes associated with rare neurological and neurometabolic diseases. For the analysis of defects in neurotransmission associated with rare neurometabolic diseases, different types of brain organoids have been made available during the last years including forebrain, midbrain and cerebral organoids. In this review, we illustrate reprogramming of somatic cells to iPSCs, differentiation in 2D and 3D, as well as already available disease-specific iPSC models, and discuss current and future applications of these techniques.
Introduction
Since their first description in 2006 Yamanaka 2006, Takahashi et al. 2007a, b) , induced pluripotent stem cells (iPSCs) have shown great potential as a model to study the pathogenesis of human disease and to evaluate therapeutic approaches. Traditionally, the pathophysiology of specific human diseases was studied in human or immortalized cell lines or animal models. Unfortunately, immortalized cells often do not respond like primary cells and animal models do not exactly recapitulate human disease (Perlman 2016) . These limitations and the ethical issues associated with the usage of human embryonic stem cells (ESCs) can be circumvented with patientderived, disease-specific iPSCs. Generally, pluripotent stem cells (PSCs) are capable of unlimited self-renewal and able to differentiate into all cell types of the three germ layers (Evans and Kaufman 1981; Martin 1981) , making them interesting also as a source for cell replacement therapies. Since 2006, many disease-specific iPSC lines have been generated. With the ability to differentiate iPSCs into specialized somatic cell types in 2D and the invention of 3D organoid culture, research on human disease was significantly pushed forward.
A short history of pluripotent stem cell research
PSCs including ESCs and iPSCs can be generated using different techniques. In 1981, Gail Martin reported the first successful isolation of mouse ESCs from the inner cell mass of a blastocyst-stage mouse embryo. In 1998, Thomson et al. re- ported the isolation of the inner cell mass of a developing human embryo resulting in the successful generation of the first human ESC lines. However, this approach is associated Communicating Editor: Saskia Brigitte Wortmann Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10545-018-0225-9) contains supplementary material, which is available to authorized users.
with severe ethical concerns and led to the search for alternative sources of PSCs. One alternative was single blastomere isolation, which was developed in 2006 by Chung et al. (2006) for mouse ESCs and in the same year adapted for hESCs (Klimanskaya et al. 2006) . With this technique, one blastomere of a morula was isolated and expanded to give rise to a new hESC line. Nevertheless, the availability of human multicell-stage embryos is very low and single blastomere isolation is not widely used in research.
W i t h t h e i r l a n d m a r k d i s c o v e r y o f c e l l u l a r reprogramming in 2006/07, Takahashi and Yamanaka opened up a new era of stem cell research circumventing all ethical issues associated with ESCs. By introducing four selected genes (Oct4, Sox2, Klf4, and c-Myc (OSKM)) into mouse (2006) and human (2007) fibroblasts, they were able to generate iPSCs. These cells resemble ESCs in morphology, gene expression, proliferation, and teratoma formation (Hochedlinger and Jaenisch 2006; Takahashi and Yamanaka 2006; Takahashi et al. 2007a, b; Wernig et al. 2007 ). However, first reprogramming strategies were inefficient (0.01-0.02%; Takahashi et al. 2007a, b; Yu et al. 2007; Aasen et al. 2008 ) and overexpression of proto-oncogenes (c-Myc, Klf4) raised safety issues. Furthermore, lentivirus-or retrovirus-based delivery of reprogramming factors results in genomic integration, which limits the applicability of these cells for therapeutic purposes due to the possibility of insertional mutagenesis. To date, mostly fibroblasts are used for reprogramming (80% of published reprogramming experiments; Gonzalez et al. 2011) as they can easily be obtained from the patient's skin and are easy to cultivate. But also other cell types have been used to generate iPSCs (keratinocytes, cord blood CD133 + cells, peripheral blood mononuclear cells (PBMCs); Aasen et al. 2008; Giorgetti et al. 2009; Su et al. 2016) . Successful reprogramming highly depends on the efficient delivery and suitable expression of the reprogramming factors used. Although it represents a quite simple technique, efficiency differs depending on the cell type used, the species, and the delivery method. Therefore, numerous protocols have been developed to improve somatic reprogramming (see Supplementary Table) including, amongst others, the use of additional genes such as UTF1, SALL4, L-Myc, TERT, SV40 LT (Niwa 2007; Zhao et al. 2008; Tsubooka et al. 2009; Park et al. 2008c) , and micro RNAs (miR-290 cluster, miR-302 cluster; Mallanna and Rizzino 2010), but also the application of diverse chemical compounds (5′azacytidine, trichostatin A, valproic acid; Huangfu et al. 2008) . Depending on the purpose of research, either integrative (lenti-or retrovirus) or non-integrative methods (Sendai virus, protein, mRNA) can be used for reprogramming. Nevertheless, there exists no optimal reprogramming strategy that is applicable for all purposes.
Induced pluripotent stem cells as disease models
Today, iPSCs are widely used for a variety of different applications, including monogenic and multigenic disease modeling, drug screening, toxicity testing, differentiation, therapeutic screening, and autologous cell therapy. Disease modeling with iPSCs is very attractive as for most human diseases no fitting in vitro models exist, due to the limited access to patient's tissues and due to the difficulties in keeping specific somatic cell types in culture. Patient-derived iPSCs now allow for the study of disease phenotypes in a dish (Egashira et al. 2011 ) including a broad variety of (neurological) diseases like Parkinson's disease (PD; Byers et al. 2012 ), Alzheimer's disease (AD; Mungenast et al. 2016) , bipolar disorders, schizophrenia, and others (lysosomal storage diseases, neurotransmitter biosynthesis defects, tetrahydrobiopterin deficiencies; Table 1 ).
Moreover, recent advances in the differentiation of iPSCs now offer the unique possibility to generate defined lineages of neural and glial cells for the studies. Directed differentiation into disease-relevant cell types allows for comprehensive molecular analyses of different disease states and for the specification of molecular phenotypes in neurodegeneration (Heman-Ackah et al. 2016) . The combination of patientspecific iPSCs with precise and flexible tools for gene editing like clustered interspaced short palindromic repeats (CRISPR)/Cas9 endonuclease, zinc finger nucleases (ZFN), site-specific nucleases (SPN), and transcription activator-like effector nucleases (TALENs) will help to further deepen our knowledge on the pathophysiology of neurodegenerative diseases.
2D differentiation
The ectoderm is the first germ layer which emerges during gastrulation and is initiated by formation of the primitive streak within the epiblast. Ectodermal cells differentiate mainly into the epidermis (skin, hair, nails, sweat glands, sebaceous cutaneous glands) and the nervous system (central and peripheral). Vertebrate nervous system development is spatially and temporally tightly regulated by gradients of signaling molecules of the bone morphogenic protein (BMP) and TGF-ß/ activin/nodal family (Morizane et al. 2011) together with DLK 1 (Surmacz et al. 2012) . Since the first report of hiPSCs in 2007, divergent protocols for their differentiation into brain-specific cell types (dopaminergic, GABAergic, glutamatergic, cholinergic and serotonergic neurons, oligodendrocytes, astrocytes, microglia; Table 2) have been established. All of these differentiation protocols follow the principles of embryonic brain development and patterning, which is determined by the spatial and temporal expression of specific morphogens along the anterior-posterior (A-P) and the dorso-ventral (D-V) axes of the embryo. A-P patterning is determined predominantly by WNT, fibroblast growth factor (FGF), and retinoic acid (RA) signaling. Activation of WNT signaling in a dose-dependent manner is sufficient to induce differentiation of iPSCs to forebrain, midbrain, hindbrain or anterior cord progenitor cells (Kirkeby et al. 2012) . WNT signaling is also important in D-V patterning where it is necessary to caudalize neural progenitor cells (Xi et al. 2012 ), but D-V patterning is mainly achieved by sonic hedgehog (SHH) and BMP signaling. Inhibition of WNT and BMP pathways promotes a dorsal fate, whereas SHH signaling determines a ventral fate of neural progenitor cells. Therefore, by precise application of morphogens and accessory activating or inhibiting molecules, iPSCs can be guided into specific types of neurons and glial cells. To promote neural differentiation, dual SMAD inhibition using inhibitors of BMP and TGF-ß signaling is widely used Chambers et al. 2009 ). Subsequently, a short overview on the currently available differentiation protocols will be given (see also Table 2 ).
Neural differentiation
Differentiation into dopaminergic neurons Dopaminergic (DA) neurons can be found in ventral midbrain regions (substantia nigra (SN), ventral tegmental area (VTA)), but also in the posterior hypothalamus (Dahlstroem and Fuxe 1964) . Midbrain dopaminergic neurons are the main source of DA in the central nervous system (CNS). DA neurons play a crucial role in the reward system, in the regulation of motor Soldner et al. 2009; Cooper et al. 2010 Cooper et al. , 2012 Devine et al. 2011; Nguyen et al. 2011; Seibler et al. 2011; Imaizumi et al. 2012; Jiang et al. 2012; Rakovic et al. 2013; Sánchez-Danés et al. 2012 , Reinhardt et al. 2012 ) generated on a xeno-free, chemically defined matrix. In the meantime, protocols were developed using defined matrices generating cells suitable for therapeutic applications or with the focus on increasing yields of dopaminergic neurons (Fedele et al. 2017; Nolbrant et al. 2017 ).
Differentiation into glutamatergic neurons
One of the most important neuronal subtypes in the CNS is glutamatergic neurons as glutamate is the major excitatory neurotransmitter in the CNS. Glutamatergic neurotransmission is interconnected with many other neurotransmitter pathways. Consequently, dysfunction has profound effects. Excess release of glutamate can induce hyperexcitability in postsynaptic neurons resulting in excitotoxicity and cell death (Choi 1994; Doble 1999) . To induce glutamatergic differentiation, several protocols have been developed. In 2012, Shi et al. reported the differentiation of cortical pyramidal neurons. Progenitor cells with glutamatergic neuronal fate were characterized by expression of FOXG1, PAX6, OTX1/2, EMX1, and TBR2. With dual SMAD inhibition in combination with RA, they could show that differentiation towards a dorsal forebrain fate became favored. Moreover, the authors could demonstrate that the time-dependent appearance of neuronal subtypes in a dish during differentiation reflects the sequential formation of the cortical layers in vivo. In parallel, Mariani et al. (2012) independently developed a protocol for the generation of cortical glutamatergic neurons by using dual SMAD inhibition, suppression of WNT signaling, and application of FGF2. Yu et al. (2014) reported a protocol which used inhibition of BMP, TGF-ß, and WNT signaling together with cyclopamine, Wnt3a, and brain-derived growth factor (BDGF) to induce differentiation into hippocampal dentate gyrus (DG) granule cells. The protocol recapitulates important steps in hippocampal neurogenesis in vivo.
Differentiation into GABAergic neurons
GABA is the main inhibitory neurotransmitter in the brain. Misregulations in the GABAergic system are linked to schizophrenia and depression. GABAergic neurons can be subdivided into spiny GABAergic neurons and GABAergic interneurons. Progenitor cells of medium spiny GABAergic Kirkeby et al. 2012; Denham et al. 2012; Xi et al. 2012; Doi et al. 2014; Adil et al. 2017; Fedele et al. 2017; Nolbrant et al. 2017 neurons (MSNs) predominantly arise from the lateral ganglionic eminence (LGE) of the telencephalon (Olsson et al. 1995; Campbell 2003) , whereas GABAergic interneuron progenitors come from the medial gangliogenic eminence (MGE) and the caudal gangliogenic eminence (CGE) located in the ventral part of the forebrain (Arlotta et al. 2008; Fode et al. 2000; Puelles et al. 2000 : Toresson et al. 2000 . The first experiments on GABAergic differentiation were unsatisfying as differentiation efficiency of striatal GABAergic neurons was low (Aubry et al. 2008; . Therefore, Ma et al. (2012) developed a protocol where they first generated an enriched population of LGE-like progenitors by using SHH or purmorphamine, which was then terminally differentiated to DARPP32-expressing MSN. These DARPP32 
Differentiation into serotonergic neurons
Serotonergic neurons are predominantly found in the raphe nucleus of the hindbrain where they arise from ventral hindbrain progenitors which are specified by a WNT gradient along the A-P axis (Matthews and Harrison 2012; Alonso et al. 2013) . Serotonin plays important roles in perception, regulation of sleep, appetite, and body temperature, but also in the sensation of pain and lack of serotonin has been associated with depression. Although many differentiation protocols for other neuronal subtypes have been published, efficient methods for the generation of serotonergic neurons are scarce. 
Differentiation into cholinergic neurons
Cholinergic neurons exist as striatal cholinergic interneurons or as basal forebrain cholinergic projection neurons. Together, they comprise the forebrain cholinergic system. All cholinergic interneurons and forebrain cholinergic projection neurons share a common developmental origin in the ventral telencephalon. Nearly all ventral forebrain cholinergic neurons arise from NKX2.1 + progenitor cells. NKX2.1 induces expression of LHX8. LHX8 is, together with ISL1, GBX1, and GBX2, necessary for the specification of a cholinergic phenotype. The first report on directed differentiation of hESCs to cholinergic cell types was published in 2010 (Nilbratt et al. 2010) where they used neurospheres in floating culture to generate, besides other neuronal cell types, also cholinergic neurons expressing cholinacetyltransferase (ChAT) and nicotinic and muscarinic acetylcholine receptors (nAChR, mAChR). In 2011, Bissonnette et al. generated basal forebrain cholinergic neurons (BFCNs) using a multistep protocol. The differentiated neurons expressed all cholinergic markers including ChAT and were able to engraft into murine brain slices. An alternative stepwise differentiation protocol was published by Crompton et al. (2013) where they first induced basal forebrain NSCs which were then further differentiated using a 3D non-adherent differentiation system producing high numbers of cholinergic neurons which express ChAT, VAChT, and ISL1 and show electrophysiological properties comparable to mature cholinergic neurons. In 2016, Yao and colleagues proposed a protocol for the generation of BFCNs using co-culture with astrocytes. They used an embryoid body (EB) step to induce primitive neuroepithelial cells which are then patterned with SHH and purmorphamine. After formation of MGEs, cells were specified towards BFCNs using low SHH and NGF in combination with co-culture on astrocytes. At day 35, 40% of the cells express ChAT, NKX2.1, ISL1, and FOXG1. After 45 days, mature neuronal markers were present including synapsin and VAChT.
Glial differentiation
Glial cells are the most abundant cell types in the brain and make up about 90% of total cells. Glial function is critical for normal brain function and nonfunctional glia is involved in a wide range of neurological disorders such as multiple sclerosis, PD, brain ischemia, spinocerebellar ataxia, ALS, and Huntington's disease (Phatnani and Maniatis 2015; Yates 2015) . Astrocytes and oligodendrocytes originate from neuroepithelial cells after neurogenesis, whereas microglia are macrophages originating in the yolk sac and migrating into the brain.
Differentiation into astrocytes
Astrocytes are specialized glial cells exerting many essential functions in the healthy CNS, including primary roles in synaptic transmission and processing of information by neural circuit functions. They respond to CNS damage through reactive astrogliosis, which is a pathological hallmark of CNS structural lesions. Astrocytes are generated from radial glia or neural stem cells (NSCs) at the subventricular zone (SVZ). As the molecular signals guiding astrocyte differentiation in vivo are not fully understood yet, most differentiation protocols follow a three-step protocol. First, hPSCs are specified to neuroepithelial cells using either EB formation or dual SMAD inhibition. Second, neuroepithelial cells are expanded until onset of gliogenesis. Glial progenitors are defined by expression of NF1A, S100b, and CD44 combined with downregulation of PAX6. Third, glial progenitors are differentiated to astrocytes in the presence of BMPs and ciliary neurotrophic factor (CNTF) via activation of STAT3 signaling. Maturation of astrocytes is defined by expression of GFAP, presence of rectifying inward K + currents, propagation of Ca 2+ waves across cells, and uptake of glutamate and takes a long time ) which were capable of glutamate uptake and promotion of synaptogenesis and became mature upon transplantation into the mouse brain. As many subtypes of astrocytes exist, which can be characterized based on their morphology, location, molecular signature, and physiological function, a functional characterization of the generated astrocytes is essential.
Differentiation into oligodendrocytes
Oligodendrocytes are the myelinating cells of the CNS. Due to their specialized metabolism (high metabolic rate, high intracellular iron, and low concentration of glutathione), they are very vulnerable to oxidative damage and mitochondrial injury. Moreover, demyelination and oligodendrocyte death are often observed under inflammatory conditions in the brain. Oligodendrocytes develop from neural stem cells late during embryonic development. They originate from the ventral neural tube (MGE, LGE, pMN), dorsal neural tube, and SVZ (Gallo and Deneen 2014; Goldman and Kuypers 2015) and arise from oligodendrocyte progenitor cells (OPCs). The best characterized origin is at the ventral part of the telencephalon and the spinal cord. Here, OPCs are specified in response to SHH signaling which induces expression of OLIG 1 and 2 (Lu et al. 2002; Zhou and Anderson 2002) , a principle mimicked by most of the differentiation protocols available to date (Table 2) .
In 2005 Table 2 ) or for the production of high cell numbers (Rodrigues et al. 2017 ).
Differentiation into microglia
Microglia represents the only lifelong resident immune cell population in the CNS and originates from the yolk sac. The cells migrate into the developing brain where they complete their differentiation. These highly specialized macrophages play a crucial role in neurodegenerative diseases including AD, PD, and ALD. Protocols for the differentiation of hPSCs to bona fide microglia are scarce. In 2016, Muffat et al. reported the generation of microglia-like cells from hESCs which recapitulate the expected ontogeny of microglia and show characteristics similar to their in vivo counterparts. Moreover, these cells resemble primary fetal human microglia. In 2017, several groups independently developed new differentiation protocols for microglia (Pandya et al. 2017; Haenseler et al. 2017; Douvaras et al. 2017; Abud et al. 2017) . Pandya et al. (2017) and Haenseler et al. (2017) used co-culture with either astrocytes or iPSC-derived cortical neurons for the generation and maturation of the microglia. Their microglia expressed key microglia-specific markers (GAS6, PROS1, TREM2, TMEM119), developed highly dynamic ramnifications, and was phagocytic. Upon activation, the microglia became amoeboid and released microglia-relevant cytokines (IL-6, IL-8, IL-10). In contrast to these co-culture protocols, Douvaras et al. (2017) developed a protocol in a chemically defined medium mimicking embryonic development. Their microglia had similar morphology and gene expression as compared to human primary microglia, and was capable of phagocytosis and cytokine release. As mutations in microglia-expressed genes have been associated with pathogenesis and disease progression of a variety of human cells, patient-derived hPSC-derived microglia can serve as model to study the role of those genes in disease development and progression.
For all cells generated via 2D differentiation protocols, it is important to test for maturity and functionality. Therefore, besides showing marker gene expression of the desired cell type, functional assays are mandatory. These include, depending on the cell type differentiated, electrophysiological measurements of postsynaptic activity, fired action potentials and specific currents present in mature cells (inward K + currents, Ca 2+ waves), specific metabolic assays (low glutathione, high metabolic rate, glutamate uptake), neurotransmitter production and release, cytokine production and release, and phagocytosis.
3D differentiation
As the brain is an extremely complex structure with subtypes of cells well organized in 3D, the development of 3D organoid culture systems starting from hPSCs has opened up new ways to study brain development in health and disease (Table 3) . 3D organoids are able to accurately recapitulate defects in early brain development as nicely shown for microcephaly by Lancaster et al. (2013) and Zika virus infection by Qian et al. (2016) . The first 3D culture presenting with intact tissue architecture generating self-organizing optic cups was reported in 2011 by Eiraku et al. It was the first study to show that neural tissue maintained in a 3D environment and floating culture is capable of self-organization into histologically correct tissue structures. In 2012, Nakano et al. presented a protocol for efficient generation of optic cups using reduced serum concentration (1.5-2%) in combination with early inhibition of WNT signaling, usage of extracellular matrix (ECM; Matrigel®), and activation of Hedgehog signaling. In 2012, Mariani et al. generated organoids resembling human dorsal telencephalon. These structures contained radial glia cells, intermediate progenitor cells, and layer-specific cortical neurons arranged in a pattern similar to the organization in vivo. The generation of 3D brain organoids originally arose from the combination of EB differentiation in the absence of growth factors or serum and embedding into Matrigel®. As no inductive signals were present, these 3D structures generated brain tissues with a variety of brain regional identities including hindbrain, midbrain, forebrain, and retinal tissues (Lancaster et al. 2013, Lancaster and Knoblich 2014a) . The dorsal forebrain regions of these cerebral organoids exhibited highly expanded progenitor zones. Moreover, neurons showed proper localization to the basal surface and a structural organization reminiscent of an intermediate zone (IZ). A similar organization was shown by Kadoshima et al. (2013) , which generated forebrain-specific organoids. The group could identify three neuronal zones (subplate, cortical plate, Cajal-Retzius cell zones) and three progenitor zones (ventricular, subventricular, and intermediate zones) present in the same apical-basal order as present in the human fetal cortex at the early second trimester. A combination of dual SMAD inhibition with floating culture was shown to generate various neural and glial identities of the dorsal cortex, especially neurons of both the deep and superficial cortical layers, in so-called cortical spheroids (Paşca et al. 2015) . Again in 2015, Muguruma et al. presented a protocol for the generation of cerebellar organoids. Sakaguchi et al. (2015) reported 3D differentiation of hESCs to hippocampal organoids. In 2016, Qian et al. were able to generate forebrain, midbrain, and hypothalamic organoids which were helpful to study the effects of Zika virus infection. Importantly, the group also introduced 3D printed mini bioreactors which enable the use of organoid technology also for high-throughput analyses. Jo et al. (2016) developed a method to generate midbrain-like organoids (MLOs) which contain distinct layers of neurons expressing midbrain-specific markers. Generally, organoid culture is more complex than classical 2D cell culture. Moreover, to maintain 3D cultures at later stages, a high oxygen environment (40%) is a prerequisite Lancaster et al. 2013, Lancaster and Knoblich 2014a, b; Camp et al. 2015; Wells et al. 2016; Garcez et al. 2016; Dang et al. 2016; Cugola et al. 2016; Lindborg et al. 2016 Forebrain organoid Autism spectrum disorder, Zika virus infection Mariani et al. 2012 Mariani et al. , 2015 Kadoshima et al. 2013; Qian et al. 2016; Xu et al. 2016 ( Eiraku et al. 2011; Kadoshima et al. 2013; Sakaguchi et al. 2015) , as well as agitation of the cultures either in a spinning bioreactor or on an orbital shaker (Lancaster et al. 2013, Lancaster and Knoblich 2014a; Qian et al. 2016) . Furthermore, many 3D methods require manual steps such as embedding of cerebral organoids into Matrigel®. Currently, 3D organoids are able to recapitulate human fetal brain development up to mid-gestation (19-24 weeks gestation; Paşca et al. 2015; Qian et al. 2016) . Later stages are not available due to insufficient oxygen supply. Moreover, neuronal studies in 3D need at least 30-40 days of culture but can last up to 100 days if synaptic maturation is to be tested. Furthermore, 3D organoids are highly complex structures and more heterogeneous compared to 2D differentiated cells. The spontaneous self-organization of organoids results in variability in morphology between the different areas of the tissue and between different experimental batches. This high inherent heterogeneity automatically leads to issues regarding reproducibility and is not well compatible with high-throughput analyses with the need for robust and reliable readout. Therefore, 3D organoids are good models to test for hypotheses where morphological analyses can be performed, like studies on microcephaly or Zika virus infection (Lancaster et al. 2013; Gabriel et al. 2017; Cugola et al. 2016; Dang et al. 2016; Garcez et al. 2016; Qian et al. 2016) where changes in phenotype are dramatic. Thus, for the study of disease pathogenesis, 3D organoid models are currently most useful when testing specific hypotheses associated with strong phenotypes.
Conclusion
iPSCs have revolutionized stem cell-based research in the field of human disease modeling. The technique is very helpful for the analysis of mono-and polygenic diseases as iPSCs can be differentiated into the mostly affected cell types including different neural cell types and glial cells. Moreover, with the invention of 3D organoid cultures, it became possible to study defective developmental processes associated with the underlying human disease. This is particularly important for research on polygenic diseases where animal models often are not sufficient and useful. Nevertheless, some problems associated with the generation of iPSCs still have to be solved, including the inherent epigenetic differences found to be present in iPSCs after reprogramming. Therefore, a genome-wide epigenetic characterization of iPSCs and their genetic stability is crucial before iPSCs can be used for therapeutic applications. Nevertheless, iPSCs still represent a powerful tool to study human disease. 
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